



## MARKET DATA

Symbol	QTXB.OB
Exchange	OTC BB
Share Price	\$0.93
Shares Outstanding	41.7M
Market Cap:	\$38.8M

## RECENT DEVELOPMENTS

**Tremendous Market Opportunity:** QuantRx's product suite addresses several high growth markets that represent over a \$5 billion opportunity. The Company's imaging agents focus on the rapidly growing PET imaging market with initial indications for cardiovascular disease, the leading cause of death in the U.S. PET as an imaging modality is growing at a CAGR of 11%. Rapid Diagnostic POC represents a growing market as new uses are developed and self-medication and diagnosis becomes more affordable. The market is currently about two billion and growing at 10%. The major segments include infectious disease, reproduction and women's health, and cancer detection.

**Robust Patent Portfolio:** QuantRx considers its Intellectual Property to be a major asset. As such, the Company has made significant efforts to assure that all of its technology is protected in all intended world markets. The Company intends to aggressively pursue additional protection to assure its continued competitive edge in the diagnostics market. This results in the longest possible term of protection of our technologies.

**QuantRx and its subsidiaries have 14 patents issued, 11 patents pending, and 12 licensed patents.**

- 12 Patents related to POC Diagnostics technology
- 10 Patents related to Molecular Imaging technology
- 15 Patents related to PAD technology

**Marquee Corporate Partnerships.** QuantRx has entered into two multi-year, multimillion-dollar corporate partnership agreements. The Company signed a licensing agreement with The Procter & Gamble Company (NYSE: PG) that allows it to incorporate patented P&G technologies into its PAD products for a number of healthcare markets. QuantRx has also entered into agreements to develop RapidTest POC products for ALT BioScience in oral care, and with a major consumer health company in feminine care.

**Multitude of Licensing Opportunities.** QuantRx has multiple opportunities to leverage its Lateral Flow and PAD technologies. Each technology has multiple product or indication possibilities. QuantRx is developing both urine and oral fluid based tests for the \$300 million U.S. drugs-of-abuse testing markets, as well as infectious disease tests, and feminine health over-the-counter disposable products for both the \$80 million U.S. hemorrhoid and \$1.4 billion U.S. feminine hygiene markets. Each product or indication has multiple corporate partnership and distributorship opportunities. The Company is currently in discussion with a number of leading life science companies.

## PRODUCT AND PRODUCT CANDIDATE PIPELINE

### Lateral Flow Diagnostics

RapidSense® point-of-care testing products based on QuantRx core intellectual property related to lateral flow techniques for the consumer and healthcare professional markets.

### Molecular Imaging

Molecular imaging agents for Positron Emission Tomography (PET) and fluorescence imaging, with initial application in cardiovascular disease, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment.

### Genomic Testing

Single Nucleotide Polymorphism (SNP) chips; genome-based diagnostic chips for the laboratory and healthcare professional markets.

### PAD/Health and Wellness

PAD technology for diagnosis and treatment of hemorrhoids, minor vaginal infection, urinary incontinence, and other medical needs.



**QuantRx Biomedical**  
100 S. Main Street, Suite 300  
Doylestown, PA 18901  
Phone: 267-880-1595  
[www.quantrx.com](http://www.quantrx.com)



**Walter Whitoshkin**  
President, Director, & CEO

## Company Description

QuantRx Biomedical is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by either medical professionals or consumers, QuantRx is focused on providing more accurate, reliable and faster diagnoses that result in improved patient care. The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of \$4 billion worldwide. The Company's technology portfolio, leveraging 15 patents and licenses, includes RapidSense® point-of-care testing products, based on QuantRx core intellectual property related to lateral flow techniques that rapidly provide medical information directly to the healthcare provider or patient.